Drug Search Results
More Filters [+]

Bezafibrate

Alternative Names: bezafibrate
Latest Update: 2023-11-13
Latest Update Note: News Article

Product Description

Bezafibrate is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) with antilipidemic activity. Bezafibrate decreases triglyceride levels, increases high density lipoprotein (HDL) cholesterol levels, and decreases total and low density lipoprotein (LDL) cholesterol levels.

Mechanisms of Action: PPAR-a Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Cyprus | Ecuador | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Israel | Italy | Korea | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Portugal | Romania | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Intercept
Company Location: NEW YORK NY 10001
Company CEO: Jerome Durso
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bezafibrate

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Biliary Cirrhosis|Cholangitis|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

-

P2

Active, not recruiting

Biliary Cirrhosis|Cholangitis

2025-10-20

NCT05239468

P2

Active, not recruiting

Biliary Cirrhosis|Liver Cirrhosis|Cholangitis

2024-08-01

NCT05239468

P2

Active, not recruiting

Biliary Cirrhosis|Liver Cirrhosis|Cholangitis

2024-08-01

Recent News Events